JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Order Through VWR & Receive a FREE Sample

Support: [email protected]

Track Your Order

Home
Bioactive Compounds
Signaling Pathways

Signaling Pathways

A2949 Linifanib (ABT-869)

Target: VEGFR|PDGFR

Summary: VEGFR/PDGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.75 mg/mL
A1185 BMS-754807

Target: Insulin and Insulin-like Receptors

Summary: IGF-1R/InsR inhibitor,potent and selective

≥23.05 mg/mL
A5078 KU-0063794

Target: mTOR

Summary: MTORC1 and mTORC2 inhibitor

insoluble in H2O; insoluble in EtOH; ≥11.65 mg/mL
A2552 Quercetin dihydrate

Target: PI3K|PIM1 kinase|phospholipase A2

Summary: PLA2 and PI 3-kinase inhibitor

≥33.8 mg/mL
A1337 U0126-EtOH
10 Citation

Target: MEK

Summary: MEK1/2 inhibitor

≥21.33 mg/mL
A1723 Roscovitine (Seliciclib,CYC202)
2 Citation

Summary: CDK inhibitor,potent and selective

insoluble in H2O; ≥17.72 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A2213 17-DMAG (Alvespimycin) HCl
1 Citation

Target: HSP90

Summary: Hsp90 inhibitor

≥26.2 mg/mL
A1882 Cediranib (AZD217)

Target: VEGFR

Summary: VEGFR inhibitor receptor,highly potent

≥22.52 mg/mL
A1767 Entecavir Hydrate

Summary: Antiviral drug used in hepatitis B infection

insoluble in EtOH; insoluble in H2O; ≥9.7 mg/mL